

Supplementary Table 1. Description of CD patients.

Sample	Disease status ¹	Leukocyte Count ²	Lymphocyte count ²	Therapy (active ingredient) ³	Steroids	Immunosuppressors
IC1	Active	15.9 x 10 ³ /μL	0.7 x 10 ³ /μL	Prednisone	Yes	No
C1	Active	3.5 x 10 ³ /μL	0.7 x 10 ³ /μL	Azathioprine + Budesonide + Spiraxin	Yes	Yes
C2	Active	7.5 x 10 ³ /μL	2.0 x 10 ³ /μL	Methylprednisolone + Metronidazole + Ciprofloxacin + Paracetamol + Pantoprazole	Yes	No
C3	Active	5.6 x 10 ³ /μL	1.2 x 10 ³ /μL	Budesonide + Mesalazine + Azathioprine + Tardiferon	Yes	Yes
C4	Active	9.2 x 10 ³ /μL	1.7 x 10 ³ /μL	Azathioprine + Budesonide	Yes	Yes
C5	Active	6.5 x 10 ³ /μL	2.0 x 10 ³ /μL	Mesalazine + Resincholestyramine	No	No
C6	Active	10.3 x 10 ³ /μL	3.1 x 10 ³ /μL	Adalimumab	No	No
C7	Debut (active)	5.1 x 10 ³ /μL	1.3 x 10 ³ /μL	Methylprednisolone + Metronidazole + Ciprofloxacin + Omeprazole	Yes	No
C8	Active	6.7 x 10 ³ /μL	1.7 x 10 ³ /μL	Azathioprine + Budesonide	Yes	Yes
C9	Inactive	9.9 x 10 ³ /μL	2.5 x 10 ³ /μL	Inflizimab + Atorvastatin + Ferrosanol	No	No
C10	Active	5.8 x 10 ³ /μL	2.5 x 10 ³ /μL	Mesalazine + Budesonide	Yes	No

¹The definition of activity followed the Harvey-Bradshaw index (HBI).

²Reference intervals are 4.5-10.8 for leukocyte count and 1.0-3.0 for lymphocyte count, respectively.

³Indications of immunosupresor and biological treatment followed the European guideline of the Inflammatory Bowel Disease from the ECCO (European Crohn and Colitis Organization). All patients that started treatment with biological drugs (n=2, 1 Infliximab, 1 adalimumab) had been correctly had their corresponding safety determinations (Mantoux, VHB).